qRT-PCR analysis of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN in colon cancer lymph nodes-An improved method for assessment of tumor stage and prognosis.
ColoNode
colon cancer
lymph nodes
prognosis
tumor markers
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
revised:
01
08
2023
received:
31
05
2023
accepted:
14
08
2023
pubmed:
13
9
2023
medline:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
One fourth of colorectal cancer patients having curative surgery will relapse of which the majority will die. Lymph node (LN) metastasis is the single most important prognostic factor and a key factor when deciding on postoperative treatment. Presently, LN metastases are identified by histopathological examination, a subjective method analyzing only a small LN volume and giving no information on tumor aggressiveness. To better identify patients at risk of relapse we constructed a qRT-PCR test, ColoNode, that determines levels of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN mRNAs. Combined these biomarkers estimate the tumor cell load and aggressiveness allocating patients to risk categories with low (0, -1), medium (1), high (2) and very high (3) risk of recurrence. Here we present result of a prospective, national multicenter study including 196 colon cancer patients from 8 hospitals. On average, 21 LNs/patient, totally 4698 LNs, were examined by both histopathology and ColoNode. At 3-year follow-up, 36 patients had died from colon cancer or lived with recurrence. ColoNode identified all patients that were identified by histopathology and in addition 9 patients who were undetected by histopathology. Thus, 25% of the patients who recurred were identified by ColoNode only. Multivariate Cox regression analysis proved ColoNode (1, 2, 3 vs 0, -1) as a highly significant risk factor with HR 4.24 [95% confidence interval, 1.42-12.69, P = .01], while pTN-stage (III vs I/II) lost its univariate significance. In conclusion, ColoNode surpassed histopathology by identifying a significantly larger number of patients with future relapse and will be a valuable tool for decisions on postoperative treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-584Subventions
Organisme : Birgit and Henry Knutsson Donation, Helsingborg Hospital
Organisme : County Council of Västerbotten
Organisme : HiloProbe AB
Organisme : Swedish Cancer Foundation
Organisme : Swedish Research Council
ID : 2017-00675
Organisme : Kempe Foundation
Organisme : Lion's Cancer Research Fund, Umeå
Organisme : Medical Faculty, Umeå University
Organisme : Stig and Ragna Gorthon Foundation
Organisme : Umeå Biotech Incubator
Organisme : VINNOVA/SweLife
Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25:1454-1455.
Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291-1305.
Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2020;40:892-910.
Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:433-441.
Iddings D, Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J Surg Oncol. 2007;96:671-677.
Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007;9:563-571.
Tsai HL, Huang CW, Yeh YS, et al. Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I-III colorectal cancer patients: a retrospective single institution cohort study of 1167 consecutive patients. BMC Surg. 2016;16:17.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43-66.
Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54:5-16.
Nguyen AT, Luu M, Nguyen VP, et al. Quantitative nodal burden and mortality across solidB cancers. J Natl Cancer Inst. 2022;114:1003-1011.
Huang A, Yang Y, Shi JY, et al. Mucinous adenocarcinoma: a unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg. 2021;13:1567-1583.
Leijssen LGJ, Dinaux AM, Amri R, et al. Impact of intramural and extramural vascular invasion on stage II-III colon cancer outcomes. J Surg Oncol. 2019;119:749-757.
Brouwer NPM, Nagtegaal ID. Tumor deposits improve staging in colon cancer: what are the next steps? Ann Oncol. 2021;32:1209-1211.
Kataoka M, Hirano Y, Ishii T, et al. Impact of lymphovascular invasion in patients with stage II colorectal cancer: a propensity score-matched study. In Vivo. 2021;35:525-531.
McClelland D, Murray GI. A comprehensive study of extramural venous invasion in colorectal cancer. PloS One. 2015;10:e0144987.
Gao Z, Cao H, Xu X, Wang Q, Wu Y, Lu Q. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes. World J Surg Oncol. 2021;19:125.
Huh JW, Lee WY, Shin JK, et al. A novel histologic grading system based on lymphovascular invasion, perineural invasion, and tumor budding in colorectal cancer. J Cancer Res Clin Oncol. 2019;145:471-477.
Pricolo VE, Steingrimsson J, McDuffie TJ, McHale JM, McMillen B, Shparber M. Tumor deposits in stage III colon cancer: correlation with other histopathologic variables, prognostic value, and risk stratification-time to consider “N2c”. Am J Clin Oncol. 2020;43:133-138.
Wang X, Cheng W, Dou X, et al. The new ‘coN’ staging system combining lymph node metastasis and tumour deposit provides a more accurate prognosis for TNM stage III colon cancer. Cancer Med. 2023;12:2538-2550.
Cohen R, Shi Q, Meyers J, et al. Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance). Ann Oncol. 2021;32:1267-1275.
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93-99.
Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:60-70.
Öberg ÅN, Lindmark GE, Israelsson AC, Hammarström SG, Hammarström ML. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAs. Int J Cancer. 2004;111:101-110.
Ohlsson L, Hammarström ML, Israelsson A, et al. Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer. 2006;95:218-225.
Olsson LM, Lindmark GE, Israelsson ACE, Korkocic D, Hammarström SG, Hammarström MLKC. CEACAM5, KLK6, SLC35D3, POSTN, and MUC2 mRNA analysis improves detection and allows characterization of tumor cells in lymph nodes of patients who have colon cancer. Dis Colon Rectum. 2021;64:1354-1363.
Ohlsson L, Lindmark G, Israelsson A, et al. Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer. Br J Cancer. 2012;107:150-157.
Olsson L, Hammarström ML, Israelsson A, Lindmark G, Hammarström S. Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis. PloS One. 2020;15:e0229007.
Ohlsson L, Israelsson A, Öberg Å, et al. Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer. 2012;130:1833-1843.
Palmqvist R, Miklos C, Fred Å, Nobin Gustafsson H, Sahibzada J. Kolon och rektum-Tumörer och tumörlika förändringar. Document name: KVAST-CRC-2022. https://medlem.foreningssupport.se/foreningar/uploads/L15178/kvast/gastro/KVAST-CRC-2022.pdf. Accessed 2022.
Loughrey MB, Quirke P, Shepherd NA. Dataset for histopathological reporting of colorectal cancer. Document number G049. In: Standards and Datasets for Reporting Cancers. www.rcpath.org/uploads/assets/c8b61ba0-ae3f-43f1-85ffd3ab9f17cfe6/G049-Dataset-for-histopathological-reporting-of-colorectal-cancer. Accessed 2018.
Regional Cancer Centra (RCC) Knowledge Bank (cancercentrum.se). National Health Care Program for Colon and Rectal Cancer version. https://kunskapsbanken.cancercentrum.se/diagnoser/tjock-och-andtarmscancer/vardprogram.pdf. Version 1.0 Accessed February 24, 2016; Version 3.1. Accessed February 3, 2023.
AbdelMageed M, Ismail HTH, Olsson L, et al. Clinical significance of stem cell biomarkers EpCAM, LGR5 and LGR4 mRNA levels in lymph nodes of colon cancer patients. Int J Mol Sci. 2021;23:403.
AbdelMageed M, Ali H, Olsson L, et al. The chemokine CXCL16 is a new biomarker for lymph node analysis of colon cancer outcome. Int J Mol Sci. 2019;20:5793.